[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Copenhagen University Hospital at Herlev\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":231},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,40,64,93,118,147,180,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100499860","implementing-ctdna-and-circular-dna-in-patients-with-localized-pancreatic-cancer-100499860",false,"NCT05788744","Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer","Implementing Non-invasive Circulating Tumor DNA and Circular DNA Analysis in Patients With Localized Pancreatic Cancer to Optimize the Pre- and Postoperative Treatment: Predicting Recurrence and Survival and Changing Prognosis Over Time","CIRCPAC","Inclusion Criteria:\n\n* Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.\n* Sub-study 2: .\n\n  * PDAC tumor stage I-III\n  * Has received intended curative resection (R0\u002FR1) of PDAC\n  * No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation\n\nExclusion Criteria:\n\n* Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion\n* Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study","ALL",{"count":19,"type":20},1000,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.",[26],"Resectable Pancreatic Cancer","RECRUITING","2026-03-24",{"date":30,"type":31},"2026-03-27","ACTUAL",{"date":33,"type":31},"2023-01-01",{"date":35,"type":20},"2032-01",{"name":37,"class":38},"Copenhagen University Hospital at Herlev","OTHER",5,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100549942","benefit-of-spectral-information-in-patients-suspected-for-lung-cancer-100549942","NCT06440616","Benefit of Spectral Information in Patients Suspected for Lung Cancer","Benefit of Spectral Information Provided by Photon Counting CT in Patients Suspected for Lung Cancer","Inclusion Criteria:\n\n* Patients suspected of lung cancer refered to Copenhagen University Hospital as per the guidelines from the danish national health authorities from either the general practitioner or from the department of pulmonology.\n* Informed consent\n\nExclusion Criteria:\n\n* Patients who cannot tolerate intravenous iodinated contrast\n* Already verified lung cancer from another institution\n* Comorbidities that exclude the patient from receiving treatment\n* Lack of reference standard in the form of either histology or follow-up\n* Known extrapulmonary malignancy\n* Technical limitations within the scans\u002Freconstructions\n* other\n\nPr. the 29th of September included 433 participants.",{"count":19,"type":20},[23],"Purpose The aim of the study is to investigate the utilization of photon counting CT (PCCT) and the spectral information provided to determine the impact of spectral information on follow-up examinations.\n\nAs secondary aims we will compare conventional CT, CT + 18Flouro-deoxy-glucose (18F-FDG) positron emission tomography (PET) and PCCT + 18F-FDG PET for the tumor-node-metastasis (TNM) staging of lung cancer patients.\n\nPCCT with and without spectral information to assess the need for additional work-up,TNM classification, and sensitivity\u002Fspecificity for malignant lesions. Patients will be randomized for reading with or without spectral information available within a clinical setting. The clinical readings are performed as a structured reports of all significant findings. Including both malignant and benign findings. Furthermore, in case additional follow-up\u002Fwork-up is needed based on the guidelines on incidental findings by the American College of Radiology (ACR), this will be reported as well. If lesions suspicious of pulmonary malignancy is present, a provisional TNM classification is provided based on the scan findings.\n\nAfter 3 months, the patient record is reviewed where additional examinations that can be attributed to the PCCT scan are recorded. The financial impact is calculated by a health economist based on the findings. PET\u002FCT, conventional CT and PCCT combined with PET will be assessed retrospectively for comparison. Endpoints are number of supplementary examinations and cost savings. Sensitivity and specificity for any malignant finding. The T, N and M stages are assessed separately as diagnostic measures by the McNemar's test with a reference standard from the Danish Lung cancer register. The number of malignant lesions will be determined by reviewing the patient records incl. pathology assessment if available 12 months after inclusion of the last patient.",[51],"Lung Neoplasm Malignant",[53,54],"Computed tomography","Spectral CT","2026-03-18",{"date":57,"type":31},"2026-03-20",{"date":59,"type":31},"2024-05-24",{"date":61,"type":20},"2027-06-01",{"name":37,"class":38},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":4,"maxAge":4,"enrollmentInfo":74,"targetDuration":76,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100630243","prevention-of-preeclampsia-in-denmark-a-national-implementation-study-100630243","NCT07485140","Prevention of Preeclampsia in Denmark: A National Implementation Study","Prevention of Preeclampsia in Denmark (PREPRED): A National Implementation Study","PREPRED","Inclusion Criteria:\n\n* Pregnant women with a viable singleton pregnancy\n* Attendance at a routine first-trimester ultrasound scan at 11+0 to 13+6 weeks of gestation at a Danish maternity hospital during the study period\n* Valid Danish personal identification number (CPR number) enabling linkage with national health registries\n\nExclusion Criteria:\n\n* Multiple pregnancy (e.g., twins or higher-order gestations)\n* Major fetal anomaly diagnosed before completion of first-trimester screening\n* Miscarriage or pregnancy loss diagnosed before completion of first-trimester screening",true,"FEMALE",{"count":75,"type":20},80000,"6 Months","OBSERVATIONAL","The goal of this clinical study is to learn if a new first-trimester screening program can better find pregnant women who are at high risk of developing preeclampsia and help prevent the condition with early treatment.\n\nPreeclampsia is a pregnancy condition that causes high blood pressure and can affect the mother's organs and the baby's growth. Early detection allows doctors to offer preventive treatment, such as low-dose aspirin, which may lower the risk of serious illness.\n\nThe study includes pregnant women with a single pregnancy who attend their routine first-trimester scan at maternity hospitals in Denmark.\n\nThe main questions it aims to answer are:\n\nDoes the new screening program lower the number of women who develop preterm preeclampsia (preeclampsia before thirty-seven weeks of pregnancy)?\n\nCan the screening program be carried out safely and be acceptable for pregnant women and healthcare professionals?\n\nResearchers will gradually introduce the new screening program across hospitals and compare outcomes before and after the program starts. Women who are found to have a high risk of preeclampsia will be offered preventive treatment with low-dose aspirin.\n\nParticipants will:\n\nReceive information about preeclampsia and the screening during their first-trimester visit\n\nHave their blood pressure measured and an ultrasound assessment of blood flow to the uterus during the routine scan\n\nHave routine blood samples analysed to estimate their personal risk of preeclampsia\n\nBe offered daily low-dose aspirin until late pregnancy if they are identified as high risk\n\nContinue standard pregnancy care while researchers follow pregnancy outcomes using national health records\n\nThe study will help researchers understand whether this screening approach works in everyday care and whether it should become part of routine pregnancy care in Denmark.",[80],"Preeclampsia (PE)",[82,83,84],"Prevention","Screening","Preeclampsia","2026-03-16",{"date":57,"type":31},{"date":88,"type":31},"2025-09-15",{"date":90,"type":20},"2027-11",{"name":37,"class":38},3,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},"100577799","optimised-post-discharge-care-in-older-patients-after-surgery-for-colon-cancer-eras-30-100577799","NCT06802991","Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)","Inclusion Criteria:\n\n* Age 65+\n* Clinical Frailty Scale preoperative score 4-7\n* Nutritional Risk Screening tool (NRS 2002) \\> 3\n* Elective colonic resection\n* No stoma planned\n* Minimally invasive surgical approach (laparoscopic or robotic)\n* Patients discharged to own home\n* Informed consent to participate\n\nExclusion Criteria:\n\n* Stoma creation during index surgery\n* Conversion to laparotomy\n* Major complications following surgery (Clavien-Dindo \\>3a)\n* Participation in other randomised trials in conflict with the protocol and end- points of the ERAS 3.0 project\n* Discharged with tube feeding and parenteral nutrition (partially or completely)\n* Known food allergies to dairy or any other ingredient contained in the nutrition package\n* Incapable of providing informed consent\n* Discharge to 24-hour municipal rehabilitation facility\n* All conditions including psychological, geographical, and social factors that could hinder adherence to the trial protocol\n* Neoadjuvant radio- or chemotherapy","65 Years",{"count":101,"type":20},60,[23],"The purpose of the study is to investigate whether an extended program (ERAS 3.0) initiated hospital discharge, can improve recovery in elderly, frail patients who have undergone surgery for colon cancer.\n\nThe study is a randomised controlled trial with two groups: an intervention group receiving the ERAS 3.0 program and a control group recieving standard care. The ERAS 3.0 program includes a comprehensive geriatric health assessment, dietary counseling from a dietitian, and instructions on training and physical activity. These activities will take place in the participant's homes after hospital discharge. Data will be collected at multiple time points: at the hospital, 12 days post-discharge (at the outpatient clinic), and at 1 and 3 months post discharge in the participants' homes.",[105,106],"Colon Cancer","Frailty",[108,109,110],"ERAS 3.0","colon cancer surgery","comprehensive geriatric assessment",{"date":55,"type":31},{"date":113,"type":31},"2025-04-01",{"date":115,"type":20},"2029-12-20",{"name":37,"class":38},2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":125,"minAge":126,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":63},"100536011","high-impact-training-to-patients-with-prostate-cancer-and-bone-metastases-100536011","NCT06259279","High Impact Training to Patients with Prostate Cancer and Bone Metastases","HIP","Inclusion Criteria:\n\n* Patients with metastatic hormone sensitive prostate cancer (mHSPC)\n* Patients must have bone metastases according to the most recent imaging (Bone scan, CT, MRI and\u002For PET)\n* Patients must be treated with androgen deprivation therapy (ADT) (orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist treatment) started \\\u003C 12 months ago. Additional treatment in the mHSPC setting, i.e., radiotherapy (RT) of the prostate, novel hormone agents (NHA) and\u002For docetaxel is permitted\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status score \\\u003C2\n* Patients must be able to speak and read Danish and provide a signed informed consent form\n* Patients must be ambulatory without walking aids\n\nExclusion Criteria:\n\n* Patients with any physical condition that interferes with the performance of physical exercise training\n* Patients with presence of any musculoskeletal, cardiovascular, or neurologic conditions that may prevent patients from exercising\n* Patients with bone pain requiring opioids\n* Patients with planned or prior palliative radiation therapy to the bone\n* Patients with major surgery within the past 6 months\n\nHIPimmune: all patients included in HIP are eligible for HIPimmune","MALE","18 Years",{"count":128,"type":20},102,[23],"HIP is a randomized controlled trial. The aim is investigate the effect, safety and feasibility of brief, high-impact exercise targeting bones in patients with prostate cancer and bone metastases. Furthermore, to investigate the effects of the intervention on bone status (bone mineral density) and body composition, physical function and performance, patient reported quality-of-life outcomes, falls and hospitalizations. The effects of resistance training on the antitumor immunity will be assessed in the peripheral blood and tumor biopsies (HIPimmune).",[132],"Prostate Cancer",[134,135,136,137,138],"bone metastases","exercise","bone mineral density","resistance and impact training","antitumor immunity","2025-02-10",{"date":141,"type":31},"2025-02-13",{"date":143,"type":31},"2024-02-06",{"date":145,"type":20},"2026-12-31",{"name":37,"class":38},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":77,"phases":4,"briefSummary":156,"conditions":157,"keywords":162,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":63},"100419452","outcome-of-dental-implant-therapy-in-patients-treated-with-antiresorptive-medication-100419452","NCT04741906","Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication","Inclusion Criteria:\n\n* Patient with cancer or osteoporosis, treated with antiresorptive treatment.\n* The patients should have sufficient compliance, this includes willingness to have the planned assessments\n* The patient should have an expected life span at enrollment of at least 2 years.\n* The local bone quality and quantity should be sufficient for implant insertion without bone augmentation and is classified according to the classification by Cawood \\& Howell 1988.\n\nExclusion Criteria:\n\n* \\> 10 cigarettes daily\n* HbA1c \\> 53 mmol\u002Fmol\n* Poor oral hygiene\n* Poor general condition: ECOG score 3 or 4.\n* Poor prognosis: Expected survival \\\u003C2 year is an exclusion cause.\n* Presence of metastases of the liver brain.\n* Poor local jaw bone quality acc. to Cawood classification stage 3 or 4.\n* Unwillingness to comply with the planned assessments and recordings",{"count":154,"type":20},225,"2 Years","Aim of the study is to examine the feasibility of dental implant insertion in patients receiving high, adjuvant and low dose \\> 4 years.",[158,159,160,161],"Missing Teeth","Implants","Cancer","Osteoporosis",[163,164,165,166,167,168,169,170,171],"Dental implants","High dose antiresorptive medication","Rehabilitation","Denosumab","Bisphosphonate","Oral rehabilitation","Adjuvant dose antiresorptive medication","Low dose antiresorptive medication","Bone modifying agents","2024-08-20",{"date":174,"type":31},"2024-08-21",{"date":176,"type":31},"2017-08-01",{"date":178,"type":20},"2025-12-31",{"name":37,"class":38},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":126,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":92},"100534090","molecularly-redefining-small-bowel-adenocarcinoma-to-accelerate-precision-patient-care-100534090","NCT06234306","Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care","SBAMOL","Inclusion criteria:\n\nPatients with histologically verified small bowel adenocarcinoma Patients older than 18 years\n\nExclusion criteria:\n\nInsufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\\&\n\nVævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.",{"count":188,"type":20},500,"Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.",[191],"Small Bowel Adenocarcinoma",[193,194,195,196],"Small bowel adenocarcinoma","messenger RNA","DNA","T-cell receptor sequencing","2024-01-29",{"date":199,"type":31},"2024-01-31",{"date":201,"type":31},"2024-01-01",{"date":203,"type":20},"2033-12-31",{"name":37,"class":38},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":155,"studyType":77,"phases":4,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":222,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":39},"100512864","danish-precocious-puberty-study---dapp-study-a-national-cohort-study-on-incidence-and-etiologies-for-precocious-puberty-100512864","NCT05957991","Danish Precocious Puberty Study - DAPP Study A National Cohort Study on Incidence and Etiologies for Precocious Puberty","Danish Precocious Puberty Study (DAPP Study) A National Cohort Study on Incidence and Etiologies for Precocious Puberty","DAPP","Inclusion Criteria:\n\n• All children (\\> 4 years of age) referred to one of the seventeen collaborating pediatric departments with one of the following diagnosis (ICD10)\n\n* DE301\n* DE228A\n* DE308A\n* DE270B\n* DE308\n* DE309\n* DZ003\n\nExclusion Criteria:\n\n* If the investigating doctor at the local hospital observes unexpected psychological\u002Fphysical reactions, or a participant is found to be unsuitable (cf. inclusion criteria) or regrets agreeing to participate, this person can at any given time be excluded.","3 Years","10 Years",{"count":216,"type":20},1500,"There is an urgent need to obtain more knowledge about the influence of weight and metabolism on the timing and progression of puberty. The age of pubertal onset has been constantly declining during the last decades and extremely early maturation may have yet unseen consequences for the psychosocial development of the child as well as detrimental long-term health consequences. Studies have shown that girls with early-onset puberty are more likely than their peers to enter sexual relationships at a younger age, to experience more psychological distress, and to engage in risk-taking behaviors. In addition, early maturation may have long-term health consequences since earlier menarche is associated with an increased risk of all-cause mortality and cardiovascular disease later in life in large epidemiological studies. The exact aetiology for the earlier onset of puberty in the general population remains to be elucidated, and the cause is probably to be found in a complex interplay between genetic, epigenetic, environmental and metabolic factors. However, world-wide there is a concerning increasing prevalence of overweight in childhood and early puberty is one of many consequences of this. Environmental factors such as endocrine disrupting chemicals have been suggested to play a role for both obesity and precocious puberty either directly or through epigenetic moderation. The current study of a Danish National cohort will explore the incidence and aetiology of precocious puberty for better treatment and prevention. Furthermore, a placebo-controlled randomized controlled trial may give a novel mechanistic insight of the interplay between insulin sensitivity and sex steroids. To our knowledge this study is the first of its kind and may lead to novel alternative treatment strategy for overweight girls with early puberty that may have beneficial effects on long-term morbidity and mortality.",[219],"Puberty, Precocious",[221],"Puberty","NOT_YET_RECRUITING","2023-07-14",{"date":225,"type":31},"2023-07-24",{"date":227,"type":20},"2023-09-01",{"date":229,"type":20},"2030-09",{"name":37,"class":38},""]